Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
M.D. Anderson Cancer Center
With
National Cancer Institute (NCI)
PRIMARY OBJECTIVES:
I. To compare the specificity of contrast enhanced MRI using a liver specific agent Eovist (gadoxetate disodium) versus the combined use of Eovist and an intravascular-extracellular agent Gadavist (gadobutrol) for the radiologic detection and characterization of liver lesions via clinical stability and follow up imaging.
OUTLINE:
Patients receive gadoxetate disodium intravenously (IV) over 1 minute and undergo MRI. Patients then receive gadobutrol IV over 1 minute at the 20 minute mark during MRI.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients with the most recent abdominal magnetic resonance (MR) study obtained within 3 months +/- 1 week
Patients with renal function (estimated glomerular filtration rate \[eGFR\] \>= 30)
Any disease type
You may not be if
Pregnant women
Patients with impaired renal function (eGFR \< 30)
Patients with surgical implants and/or metallic foreign bodies non-compatible with the MR magnet
Patients with contraindications to the use of intravenous contrast such as allergic type reactions
Clareo Health | Contrast-enhanced MRI in Detecting Benign and Malignant Liver Lesions
